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Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) infection was necessary but not sufficient for Kaposi’s sarcoma (KS)
development without other cofactors. Previously, we identified that both human immunodeficiency type 1 (HIV-1) Tat and
herpes simplex virus 1 (HSV-1) were important cofactors reactivating KSHV from latency. Here, we further investigated the
potential of herpes simplex virus 2 (HSV-2) to influence KSHV replication and examined the role of Tat in this procedure. We
demonstrated that HSV-2 was a potentially important factor in the pathogenesis of KS, as determined by production of lytic
phase mRNA transcripts, viral proteins and infectious viral particles in BCBL-1 cells. These results were further confirmed by
an RNA interference experiment using small interfering RNA targeting KSHV Rta and a luciferase reporter assay testing Rta
promoter-driven luciferase activity. Mechanistic studies showed that HSV-2 infection activated nuclear factor-kappa B (NF-
kB) signaling pathway. Inhibition of NF-kB pathway enhanced HSV-2-mediated KSHV activation, whereas activation of NF-
kB pathway suppressed KSHV replication in HSV-2-infected BCBL-1 cells. Additionally, ectopic expression of Tat enhanced
HSV-2-induced KSHV replication. These novel findings suggest a role of HSV-2 in the pathogenesis of KS and provide the
first laboratory evidence that Tat may participate HSV-2-mediated KSHV activation, implying the complicated pathogenesis
of acquired immunodeficiency syndrome (AIDS)-related KS (AIDS-KS) patients.
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Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV) was first
detected in Kaposi’s sarcoma (KS) tissues from a patient with
acquired immunodeficiency syndrome (AIDS) by representational
difference analysis [1]. The virus has been shown to correlate to all
epidemiological forms of KS, primary effusion lymphoma (PEL)
and a subset of multicentric Castleman’s disease [2–5]. Like other
herpesviruses, KSHV has two different phases in its life cycle,
latency and lytic replication. Latency was characterized by
persistence of the viral genome with expression of a limited set of
viral genes. Once KSHV was reactivated from latency and entered
the lytic cycle, most viral genes were expressed in an orderly fashion
(immediate-early, early and late), leading to the production of
infectious virions [6–8]. KSHV infection was necessary but not
sufficient for KS development without other cofactors. We and
others demonstrated that several agents, such as human immuno-
deficiency virus type 1 (HIV-1) transactivating protein Tat, herpes
simplex virus type 1 (HSV-1), human herpesvirus 6 (HHV-6),
human cytomegalovirus (HCMV) and HIV-1, have been proved to
be cofactors reactivating KSHV from latency [9–13].
While sexually transmitted infections (STI) were associated with
increased sexual transmission of HIV-1 and KS was the most
common malignant tumor in patients with AIDS, more and more
attentions were paid to the relationship of HIV-1, KSHV and the
other sexually transmitted diseases (STD) pathogens [14–17]. A
multi-center cross-sectional study in prisoners of Italian showed
that, 20.7% prisoners had antibodies against KSHV, 21.2%
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31652prisoners had anti-HSV-2 antibodies, and 7.5% prisoners were
HIV-1-positive. KSHV infection was associated with HSV-2
(P=0.004) seropositivity. At multivariate analysis HSV-2-positivity
was associated with HIV-1 (P,0.001) and KSHV infections
(P=0.003). The associations of KSHV and HSV-2 infection
suggest sexual transmission of these viruses among Italian prison
inmates [18]. In remote villages of the southwestern part of Papua
New Guinea, the seropositivity of HSV-2 independently correlated
with KSHV infection [19]. The research performed by A. Volpi et
al in Northern Cameroon draw a similar conclusion [20]. These
results suggest that HSV-2 infection was associated with sexual
transmission of KSHV. HSV-2 could infect B cells and human
vascular endothelial cells, the precursor of KS [21,22]. Although
HSV-2 and KSHV are not found in similar anatomic compart-
ments during their latent infection, both reactivation and primary
infection of HSV-2 occurred in patients, leading to appearance of
HSV-2 viraemia [23]. Viraemia subsequently increased opportu-
nities for HSV-2 to contact B and/or endothelial cells, which,
maybe, previously had harbored the KSHV genome. Additionally,
HIV-1 and KSHV do not generally infect the same cells, however,
circulating Tat was secreted from infected cells and taken up by
target cells [24], such as B and endothelial cells, which might also
be latently infected by KSHV, resulting in changes in viral and
cellular gene expression. These facts led us to hypothesize that
HSV-2 may regulate KSHV replication and Tat plays a role in
this procedure in KS or AIDS-KS patients.
To verify this hypothesis, in this study we performed kinetic
studies of KSHV replication induced by HSV-2. We found that
HSV-2 infectionofPELcell linesinducedlytic replication of KSHV
by activating Rtaand inhibition of NF-kB pathway enhancedHSV-
2-induced KSHV reactivation. Ectopic expression of Tat strength-
ened HSV-2-induced KSHV replication and Rta promoter activity.
These novel findings are believed to be the first line of laboratory
evidence that HSV-2 could influence KSHV replication and Tat
exerted the enhancing function in this procedure.
Results
HSV-2 Infection of BCBL-1 Cells Results in Lytic Cycle
Replication of KSHV
To evaluate whether HSV-2 affected KSHV replication, we
first determined the susceptibility of BCBL-1 cells to HSV-2.
HSV-2 was inoculated into BCBL-1 cells and cell morphologic
changes were observed by light microscope. As shown in Fig. 1A,
BCBL-1 cells began to exhibit cytopathic effects (CPE) since
24 hours post-infection. With time going, the number of infected
BCBL-1 cells showing the typical CPE, such as the formation of
syncytia and polykaryocytes, gradually increased. Particularly,
more than 80% of BCBL-1 cells exhibited the CPE at 120 hours
post-inoculation (Fig. 1A) while only less than 5% of Mock-treated
BCBL-1 cells showed CPE at this time point (data not shown). To
determine whether HSV-2 could replicate in BCBL-1 cells, the
mRNA expression of a HSV-2 immediate early (IE) gene, UL48,
which encodes transactivating tegument protein VP16 [25], was
detected by RT-PCR. We found that the mRNA of UL48 started
to express in BCBL-1 cells since 12 hours post-infection (pi) and
reached a peak at 24 hours pi, then decreased by degrees (Fig. 1B).
Further, the experiment was designed to detect the UL5 gene, an
early gene of HSV-2 encoding helicase-primase helicase subunit
and a late gene, US6, which encodes viral envelope glycoprotein D
(gD) [26,27]. It was demonstrated that both UL5 and US6
mRNAs began to express at 24 hours pi and gradually increased
with time going (Fig. 1B). Finally, HSV-2 structure protein gG2
(the type-specific IgG encoded by a late gene) [28] was detected by
Western blot. We found that HSV-2-infected BCBL-1 cells started
to express gG2 since 72 hours pi and continued to increase
expression of gG2 at 96 hours (Fig. 1C). These data indicated that
HSV-2 infected BCBL-1 cells and replicated.
To examine whether HSV-2 could activate KSHV replication,
RT-qPCR was performed. Analysis of data from three indepen-
dent experiments demonstrated that, on average, Rta (replication
and transcription activator, Rta; the molecular switch gene of
KSHV; also known as ORF50) [8,29] mRNA expression in HSV-
2-infected BCBL-1 cells increased 7.26-fold at 3 hours, 2.52-fold
at 6 hours, 15.77-fold at 12 hours, 20.92-fold at 24 hours, 11.44-
fold at 48 hours, 11.02-fold at 72 hours, and 2.81-fold at 96 hours,
respectively, when compared to Mock-treated BCBL-1 cells
(Fig. 2A). Meanwhile, ORF26 (viral minor capsid protein
expressed only during lytic KSHV replication) [30] mRNA
showed a similar expression pattern as Rta (Fig. 2B). To determine
whether other KSHV lytic genes were also up-regulated in HSV-
2-infected BCBL-1 cells, RT-PCR analysis was performed to
detect the expression of ORF57 and vIL-6 transcripts. All mRNAs
of these genes in HSV-2-infected BCBL-1 cells were increased
from 24 to 96 hours when compared to their corresponding
controls (Fig. 2C). These data suggest that HSV-2 might activate
KSHV lytic cycle RNA replication. Next, we asked whether
induction of KSHV lytic cycle RNA replication by HSV-2 also
resulted in induction of lytic cycle proteins, the expressions of lytic
cycle protein Rta and ORF59 were examined. As shown in
Fig. 2D, for each of the time points (24, 72 and 96 hours), the level
of Rta expression was increased in HSV-2-infected BCBL-1 cells
compared to Mock-treated cells. Similarly, the expression of
KSHV ORF59 protein was significantly increased in HSV-2-
infected BCBL-1 cells at 24 and 72 hours compared with the
corresponding control (Fig. 2E and 2F).
HSV-2 Infection of BCBL-1 Cells Results in Release of
Infectious Virions of KSHV
Theoretically, KSHV lytic cycle replication induced by HSV-2
would subsequently produce infectious progeny virions. To test this
hypothesis, experiments were designed to detect KSHV virions in
the supernatant from HSV-2-infected BCBL-1 cell cultures. The
supernatant of HSV-2-infected BCBL-1 cells was collected and
divided into two parts. The 1
st part was used for viral DNA extract.
Purified viral DNA was used for real-time DNA-PCR analysis. As
shown in Fig. 3A, KSHV viral copy number in HSV-2-infected
BCBL-1 cells was increased 4.14-fold at 72 hours when compared
to Mock-infectedBCBL-1 cells. To further determine whether these
viral particles were infectious, the 2
nd part of supernatant was
employed to infect HEK293 cells, which were previously shown to
be permissive cells for KSHV [31]. After 27 hours infection, the
total RNA was isolated and RT-PCR was performed to amplify
KSHV specific sequence, ORF26. The results demonstrated that
ORF26 mRNA was readily expressed in HEK293 cells infected
with the supernatant from HSV-2-infected BCBL-1 cells, but not in
HEK293 cells treated with the supernatant from Mock-treated
BCBL-1 cells (Fig. 3B). And vIL-6 protein was also detected in
HEK293 cells infected with the supernatant from HSV-2-infected
BCBL-1 cells by Western blot (Fig. 3C).
HSV-2 Activates KSHV Lytic Cycle Replication possibly by
Activating Rta
To explore whether HSV-2 induced KSHV replication by
activating Rta, we examined the effect of HSV-2 infection on Rta
promoter activity in several cell lines. Cells transfected with p50-
Luc demonstrated enhanced levels of luciferase expression (3.75,
Activation of KSHV by HSV-2 and Tat
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respectively) by treatment with TPA (used as a positive control).
Notably, HSV-2 infection resulted in a significant increase in
luciferase expression [1.83, 3.87, and 76.33-fold increase in BCBL-
1( P=0.039), B95-8 (P=0.001) and Vero (P=0.002) cells,
respectively] compared to the corresponding control (Fig. 4A).
To confirm this result, luciferase assays were also performed in the
other KSHV-positive cell lines, such as BC-3 (a type of PEL) and
293/Bac36. It was demonstrated that HSV-2 infection lead to a
2.31- and 1.44-fold increase in luciferase expression in BC-3
(P=0.047) and 293/Bac36 (P=0.032) cells, respectively, when
compared to the corresponding control (Fig. 4A). To extend these
results, a siRNA construct, which was previously designed to
silence KSHV Rta [11], was introduced into HSV-2-infected
BCBL-1 cells. As shown in Fig. 4B, Rta protein in HSV-2-infected
BCBL-1 cells further transfected with pRNAT-Rta was markedly
Figure 1. The susceptibility of BCBL-1 cells to HSV-2 infection. (A). The CPE on BCBL-1 cells infected by HSV-2 (original
magnification, 640). HSV-2 was inoculated into BCBL-1 cells for 0 to 120 hours and changes of cell morphology were observed under light
microscope. (B). RT-PCR analysis for HSV-2 immediate early, early, and late genes mRNA in HSV-2-infected BCBL-1 cells. HSV-2 UL48,
UL5 and US6 mRNA expression in BCBL-1 cells infected with Mock or HSV-2 for 6, 12, 24, 48, and 72 hours was detected by RT-PCR. b-Actin was
readily detectable in all samples indicating the presence of amplifiable cDNA. (C). Western blot analysis for HSV-2 structural protein
expression in HSV-2-infected BCBL-1 cells. BCBL-1 cells were infected with Mock or HSV-2 for 24, 48, 72 and 96 hours; or Vero cells were
infected with HSV-2 for 48 hours (positive control). Whole cell lysate were subjected to Western blot with the indicated antibody. Results shown are
from a representative experiment of three independent experiments with similar results.
doi:10.1371/journal.pone.0031652.g001
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controls. These observations collectively suggest that HSV-2
activates KSHV replication possibly by activating Rta.
Inhibition of NF-kB Signaling Enhances HSV-2-Induced
KSHV Replication
It has been shown that several KSHV genes and KSHV acute
infection activated NF-kB signaling pathway in different cell lines,
but the role of NF-kB during the reactivation of KSHV was still
controversial [32–37]. To examine whether HSV-2 was able to
trigger NF-kB activation in PEL cell lines, BCBL-1 cells were
infected by HSV-2 and nuclear extracts were analyzed for NF-kB
activation by ELISA-based NF-kB activity assay. As shown in
Fig. 5A, HSV-2 infection of BCBL-1 cells increased phosphory-
lated p65 in nucleus to bind consensus binding sequences for p65
of NF-kB at 12, 24 and 48 hours, while wide-type p65 competitor
oligo abolished this activation. To test the transcriptional function
of activated NF-kB in response to HSV-2, we transfected an NF-
kB-dependent firefly luciferase reporter construct into HSV-2-
infected BCBL-1 cells and measured the NF-kB luciferase activity.
We observed an apparent induction of reporter activity in BCBL-1
cells with HSV-2 infection compared to that of Mock-infected cells
Figure 2. Expression of KSHV lytic cycle RNA and protein in HSV-2-infected BCBL-1 cells. (A). Rta mRNA expression in HSV-2-
infected BCBL-1 cells. Rta mRNA expression in BCBL-1 cells infected with Mock or HSV-2 for 3, 6, 12, 24, 48, 72 and 96 hours was quantitated by RT-
qPCR. Relative quantities of Rta expression represented on the y-axis. Results shown were from three independent experiments performed in
triplicate. * p,0.05 and ** p,0.01 for Student’s t-test versus mock group, respectively. (B). ORF26 mRNA expression in HSV-2-infected BCBL-1
cells. ORF26 mRNA expression in BCBL-1 cells infected with Mock or HSV-2 for 3, 6, 12, 24, 48, 72 and 96 hours was measured by RT-qPCR. Relative
quantities of ORF26 expression represented on the y-axis. Results shown were from three independent experiments performed in triplicate. * p,0.05
and ** p,0.01 for Student’s t-test versus mock group, respectively. (C). RT-PCR analysis for ORF57 and vIL-6 mRNA in BCBL-1 cells infected
with HSV-2. ORF57 and vIL-6 mRNA expression in BCBL-1 cells infected with Mock or HSV-2 for 24, 48, 72 and 96 hours was detected by RT-PCR. b-
Actin was readily detectable in all samples indicating the presence of amplifiable cDNA. (D). Rta protein expression in BCBL-1 cells infected by
HSV-2. BCBL-1 cells were infected with HSV-2 or mock for 24, 72 and 96 h and whole-cell lysates were subjected to Western blot with Rta antibody.
The membrane was stripped and reprobed with anti-actin antibody as a loading control. Results shown are from a representative experiment of three
independent experiments with similar results. (E). Immunofluorescence assay staining of BCBL-1 cells infected with HSV-2 (original
magnification, 406). KSHV lytic protein ORF59 expression in normal BCBL-1 cells (untreated) and BCBL-1 cells infected with mock or HSV-2 for 24
and 72 h was detected by immunofluorescence assay staining with ORF59 MAb. (F). Quantification of results in (E). Quantitative and statistic
methods were described in the text. ** p,0.01 for Student’s t-test versus mock group.
doi:10.1371/journal.pone.0031652.g002
Activation of KSHV by HSV-2 and Tat
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31652at 12, 24, and 48 hours (Fig. 5B). To define the function of NF-kB
in HSV-2-induced KSHV reactivation, BCBL-1 cells were pre-
treated by DMSO or Bay 11-7082, a pharmacologic inhibitor of
IkB kinase(IKK)-NF-kB activation, for 1 hour followed by HSV-2
infection. It was demonstrated that treatment of Bay 11-7082 not
only decreased the level of p65 in the nucleus (Fig. 5C), resulting in
little amount of NF-kB binding to its DNA region in an NF-kB-
dependent reporter construct (Fig. 5D), but also increased KSHV
ORF26 mRNA and vIL-6 protein expression and viral particle
release in HSV-2-infected BCBL-1 cells (Fig. 5E, 5F and 5G). On
the other hand, transfection of IKK2EE, which was capable of
phosphorylating IkBa, not only elevated the level of p65 in the
nucleus and increased its function (Fig. 6A and 6B), but also down-
regulated KSHV ORF26 mRNA and vIL-6 protein expression
and viral particle release in HSV-2-infected BCBL-1 cells (Fig. 6C,
6D and 6E). Taken together, these data suggest that HSV-2
activated NF-kB pathway, which exhibit an inhibitory effect on
KSHV reactivation in BCBL-1 cells.
HIV-1 Tat Enhances Induction of KSHV Lytic Cycle
Replication by HSV-2
To explore whether Tat influenced HSV-2-induced KSHV
replication, BCBL-1 cells were infected with HSV-2 and then
Figure 3. HSV-2 infection of BCBL-1 cells results in release of infectious virions of KSHV. (A). Real-time DNA-PCR analysis for the
viral copy number of KSHV. BCBL-1 cells were infected with HSV-2 or Mock. At 72 hours postinfection, supernatant virus was collected,
concentrated, and used for real-time DNA-PCR analysis. Results shown were from three independent experiments performed in triplicate. ** p,0.01
for Student’s t-test versus mock group. (B). RT-PCR analysis for ORF26 mRNA in BCBL-1 or HEK293 cells treated with supernatant from
HSV-2-infected BCBL-1 cells. ORF26 mRNA expression in BCBL-1 cells treated with TPA (Lane 1), HEK293 cells treated for 48 hours with
supernatant from TPA-treated BCBL-1 cells for 72 hours (Lane 2), HEK293 cells cultured alone for 27 hours (Lane 3), HEK293 cells infected with HSV-
2 for 27 hours (Lane 4), HEK293 cells treated for 27 hours with supernatant from Mock-treated BCBL-1 cells for 72 hours (Lane 5), and HEK293 cells
treated for 27 hours with supernatant from HSV-2-infected BCBL-1 cells for 72 hours (Lane 6) were detected by RT-PCR. (C). Western blot for
detection of vIL-6 expression in BCBL-1 cells or HEK293 cells treated with supernatant from HSV-2-infected BCBL-1 cells. vIL-6
expression in BCBL-1 cells treated with TPA (Lane 1), HEK293 cells treated for 48 hours with supernatant from TPA-treated BCBL-1 cells for 72 hours
(Lane 2), HEK293 cells cultured alone for 27 hours (Lane 3), HEK293 cells infected with HSV-2 for 27 hours (Lane 4), HEK293 cells treated for
27 hours with supernatant from Mock-treated BCBL-1 cells for 72 hours (Lane 5), and HEK293 cells treated for 27 hours with supernatant from HSV-
2-infected BCBL-1 cells for 72 hours (Lane 6) were detected by Western blot.
doi:10.1371/journal.pone.0031652.g003
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ORF26 mRNA expression. ORF26 mRNA expression in HSV-2-
infected and Tat-transfected BCBL-1 cells increased 3.03-fold at
6 hours, 1.94-fold at 24 hours, 2.95-fold at 48 hours and 1.64-fold
at 72 hours, respectively, when compared to that of HSV-2-
infected and pcDNA-transfected BCBL-1 cells (Fig. 7A). These
data demonstrated that intracellular Tat enhanced ORF26
mRNA expression in HSV-2-induced KSHV lytic cycle phase.
Interestingly, the expression of ORF26 was slightly up-regulated in
Tat-transfected and mock-treated BCBL-1 cells at 6, 24, and
72 hours compared with that of pcDNA-transfected and mock-
treated BCBL-1 cells. However, our previous report showed that
intracellular Tat did not influence the expression of ORF26
mRNA in BCBL-1 cells until at 96 hours [12]. It was probably
that in this study the supernatant of Vero cell cultures contained
some soluble factors, which might have a synergetic effect with Tat
on KSHV reactivation. To investigate whether Tat has an effect
on the protein level of vIL-6, Western blot analysis was performed.
As shown in Fig. 7B, HSV-2-infected BCBL-1 cells, which were
transfected with pTat, expressed more vIL-6 at 48 and 72 hours,
compared with HSV-2-infected BCBL-1 cells transfected with
pcDNA. These data indicated that the Tat might enhance HSV-2-
induced KSHV replication.
To explore whether Tat increased HSV-2-induced KSHV
replication via activating Rta, we examined the effect of Tat on
Rta promoter activity in HSV-2-infected BCBL-1, B95-8 and
Vero cells. Rta promoter activity in pTat and p50-Luc-
cotransfected BCBL-1 cells infected by HSV-2 increased 2.48-
fold when compared to that of pcDNA and p50-Luc-cotransfected
BCBL-1 cells infected by HSV-2. Similar expression pattern of
Rta promoter activity was also observed in B95-8 and Vero cell
(Fig. 7C). Taken these results together, we speculated that Tat
enhanced the HSV-2-induced KSHV reactivation in BCBL-1 cells
by activating Rta promoter.
Figure 4. HSV-2 activates KSHV lytic cycle replication via Rta. (A). HSV-2 infection promotes induction of KSHV Rta promoter
activity. BCBL-1, BC-3, 293/Bac36, B95-8 and Vero cells were infected with Mock (Mock+p50-Luc) or HSV-2 (HSV-2+p50-Luc), or treated with TPA
(TPA+p50-Luc), and then cotransfected with the firefly luciferase reporter construct p50-Luc (0.4 mg) and a Renilla luciferase construct pRL-TK
(0.02 mg). Luciferase activities were measured, normalized to inner control, and presented as fold increase (n-fold). All data points were the averages
of three independent experiments performed in triplicate. * p,0.05 and ** p,0.01 for Student’s t-test versus Mock+p50-Luc group, respectively. (B).
Western blot analysis for Rta protein in si-construct-transfected BCBL-1 cells infected with HSV-2. BCBL-1 cells were transfected with
pRNAT-Rta or pRNAT-vector, and then infected with HSV-2 or Mock for 48 hours. Whole cell lysate were subjected to Western blot with the indicated
antibody.
doi:10.1371/journal.pone.0031652.g004
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kB pathway in BCBL-1 cells. BCBL-1 cells were infected by HSV-2 or Mock for 12, 24 and 48 hours. Then cells were collected and nuclear proteins
were extracted for ELISA-based NF-kB activity assay. Excess competitor oligonucleotides were coincubated with the nuclear protein of HSV-2-infected
BCBL-1 cells for competition assays (HSV-2+Comp.). Results presented were the statistic of three independent experiments performed in triplicate.
** p,0.01 and
## p,0.01 for Student’s t-test versus Mock and HSV-2 groups, respectively. (B). HSV-2 infection increased NF-kB activity in
BCBL-1 cells. BCBL-1 cells adsorbed with HSV-2 or Mock for 1 hour, then were transfected with an NF-kB-dependent firefly luciferase reporter
construct (0.4 mg) together with a Renilla luciferase construct pRL-TK (0.02 mg) for 12, 24 and 48 hours. Whole-cell extracts were prepared, and the
firefly as well as the Renilla luciferase activity was measured. The experiment was performed three times in parallel, and the mean 6 s.e.m is shown.
** p,0.01 for Student’s t-test versus Mock group. (C). A pharmacologic inhibitor of IKK–NF-kB activation, Bay 11-7082, inhibited the
binding activity of P65 of NF-kB pathway in HSV-2-infected BCBL-1 cells. BCBL-1 cells were pre-treated by Bay 11-7082 (5 mM) or DMSO for
1 hour followed by HSV-2 or Mock infection for 12, 24 and 48 hours. Then cells were collected and nuclear proteins were extracted for ELISA-based
NF-kB activity assay. Excess competitor oligonucleotides were coincubated with the nuclear protein of DMSO-pre-treated and HSV-2-infected BCBL-1
cells for competition assays (HSV-2+DMSO+Comp.). Results presented were the statistic of three independent experiments performed in triplicate.
** p,0.01 for Student’s t-test versus Mock+DMSO group;
## p,0.01 and
& p,0.01 for Student’s t-test versus HSV-2+DMSO group, respectively.
(D). Bay 11-7082 inhibited HSV-2-induced activity of NF-kB in BCBL-1 cells. BCBL-1 cells were pre-treated by Bay 11-7082 (5 mM) or DMSO
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glycoprotein gG of HSV-2 (Fig. 1C), we next tested the effect of
Tat on HSV-2 gG expression in BCBL-1 cells. As shown in
Fig. 7D, HSV-2-infected BCBL-1 cells consistently expressed
HSV-2 gG at 72 hours, no matter transfected with pcDNA or
pTat, which was consistent with the results of Fig. 1C at 48 hours.
Remarkably, at 48 hours, gG was detectable in HSV-2-infected
and pTat-transfected BCBL-1 cells while there was no corre-
sponding band detected in HSV-2-infected and pcDNA-transfect-
ed BCBL-1 cells (Fig. 7D), implying that overexpression of Tat
promotes HSV-2 replication. Together these data suggest that Tat
might enhance KSHV lytic cycle replication by accelerating HSV-
2 replication in BCBL-1 cells.
Discussion
The epidemical studies shown that interaction between the STIs
was complex. The relationship of HSV-2 and KSHV remains
quite controversial. Studies from three groups demonstrated that
HSV-2 and KSHV were associated in the prisoners of Italian and
some areas in Africa, which suggest that HSV-2 infection
contributed to sexual transmission of KSHV infection [18–20].
However, Malope et al have shown that in a heterosexual South
African population there was no evidence of sexual transmission of
KSHV [38].
The present work demonstrated that HSV-2 infection of BCBL-
1 cells induced KSHV replication and provided the direct
laboratory evidence that HSV-2 was a potential cofactor for
KSHV reactivation. KSHV was necessary but not sufficient in KS
development and the cofactors played an important role in the
pathogenesis of KS [8]. For instance, HIV-1 infection of PEL cell
lines induced the reactivation of KSHV through directly activating
the promoter of KSHV Rta [13,39,40]. HSV-1 could activate
KSHV replication partially by elevating the level of IL-10 and IL-
4 [11]. Here we have further demonstrated that HSV-2 was also a
critical factor responsible for the induction of KSHV replication,
suggesting that HSV-2 might promote KS progression by
increasing viral load. However, whether some soluble factors
produced in response to HSV-2 infection might also be involved in
this procedure is still unknown.
The role of NF-kB pathway during the reactivation of KSHV is
still a highly controversial and arguable subject. We and other five
groups consistently demonstrated that NF-kB signaling displayed
an inhibitory effect on KSHV reactivation [33,36,37,41–43].
However, one group showed that activation of NF-kB was
required for KSHV replication and the production of replica-
tion-competent KSHV virions [32]. Actually, Grossmann and
colleagues indicated that the relationship between NF-kB and
spontaneous KSHV reactivation was complex, non-uniform and
dependent on the cellular context. Even though NF-kB activation
is inhibitory to lytic gene expression in some contexts, such
inhibition is at least partially bypassed or overridden during lytic
growth. In this study, we indicated that HSV-2 infection of BCBL-
1 cells led to dramatic activation of the NF-kB signaling, which
was consistent with previous reports [44,45]. Furthermore,
inhibition of NF-kB significantly promoted KSHV lytic replica-
tion; elevating NF-kB signaling remarkably repressed KSHV
replication, which was in agreement with the reports of six groups
above mentioned. These observations also implied that other
signal pathways might exist together with activated NF-kBi n
HSV-2-infected BCBL-1 cells during KSHV reactivation. When
HSV-2 infected BCBL-1 cells, it must lead to alternation of
multiple signal pathways. Some activated signals facilitated KSHV
replication; inversely, others exerted an inhibitory effect, such as
NF-kB. If signals whose activation can promote KSHV replication
are always predominated, they may compensate the inhibitory
effect of NF-kB. Therefore, our results never eliminate the
possibility that some other signals produced in response to HSV-
2 infection might also be involved in this procedure.
The Tat protein of HIV-1 functioned as a transacting
transcriptional activator and was of great interest in the studies
of KS. Our previous studies demonstrated that Tat not only
induced KSHV replication, but also accelerated the tumorigen-
esis by KSHV Kaposin A in vitro and in vivo [12,46]. In the
current study, we showed that Tat could enhance the HSV-2-
induced lytic replication of KSHV. Interestingly, Tat also
accelerated HSV-2 replication in BCBL-1 cells. Given the fact
that HSV-1 and its immediate-early genes ICP0 and ICP4 greatly
stimulated the expression of HIV-1 LTR-directed viral gene
expression collaborated with Tat [47,48], and Tat increased the
transcriptional activity of HSV-1 ICP0 [48]. We speculated that,
with high homology to ICP0 and ICP4 of HSV-1 [49], the
cooperation of Tat and ICP0 and ICP4 of HSV-2 stimulated the
transcript and replication of HSV-2, which indirectly induced
KSHV replication. However, the mechanism still needs to be
elucidated.
In summary, we showed that HSV-2 was a potentially
important factor in the pathogenesis of KS and NF-kB signal
exerted an inhibitory effect in HSV-2-induced KSHV replication.
We also revealed that Tat could enhance HSV-2-induced KSHV
replication. Because HSV-2 infection of cells stimulated multiple
downstream effects [50,51] and intracellular Tat activated the
KSHV replication partially through JAK/STAT pathways [12],
further studies are needed to better understand the signaling
involved in Tat increasing HSV-2-induced KSHV reactivation
from latency.
for 1 hour followed by HSV-2 or Mock infection for 1 hour and then were transfected with an NF-kB-dependent firefly luciferase reporter construct
(0.4 mg) together with a Renilla luciferase construct pRL-TK (0.02 mg) for 12, 24 and 48 hours. Whole-cell extracts were prepared, and the firefly as well
as the Renilla luciferase activity was measured. The experiment was performed three times in parallel, and the mean 6 s.e.m is shown. ** p,0.01 and
## p,0.01 for Student’s t-test versus Mock+DMSO and HSV-2+DMSO groups, respectively. (E). Bay 11-7082 enhanced ORF26 mRNA
expression in HSV-2-infected BCBL-1 cells. BCBL-1 cells were pre-treated by Bay 11-7082 (5 mM) or DMSO for 1 hour followed by HSV-2 or Mock
infection for 12, 24 and 48 hours. ORF26 mRNA expression in BCBL-1 cells was measured by RT-qPCR. Relative quantities of ORF26 expression
represented on the y-axis. Results shown were from three independent experiments performed in triplicate. * p,0.05 and ** p,0.01 for Student’s t-
test versus Mock+DMSO group, respectively;
# p,0.05 and
## p,0.01 for Student’s t-test versus HSV-2+DMSO group, respectively. (F). Bay 11-7082
enhanced vIL-6 expression in HSV-2-infected BCBL-1 cells. BCBL-1 cells were pre-treated by Bay 11-7082 (5 mM) or DMSO for 1 hour followed
by HSV-2 or Mock infection for 12, 24 and 48 hours. Whole cell lysate were subjected to Western blot with the indicated antibody. (G). Real-time
DNA-PCR analysis for the viral copy number of KSHV. BCBL-1 cells were pre-treated by Bay 11-7082 (5 mM) or DMSO for 1 hour followed by
HSV-2 or Mock infection. At 24 and 48 hours postinfection, supernatant virus was collected, concentrated, and used for real-time DNA-PCR analysis.
Results shown were from three independent experiments performed in triplicate. * p,0.05 and ** p,0.01 for Student’s t-test versus Mock+DMSO
and HSV-2+DMSO groups, respectively.
doi:10.1371/journal.pone.0031652.g005
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31652Figure 6. Elevating NF-kB signaling inhibits HSV-2-induced KSHV replication. (A). Transfection of IKK2EE promoted the binding
activity of P65 of NF-kB pathway in HSV-2-infected BCBL-1 cells. BCBL-1 cells were infected by HSV-2 or Mock for 1 hour, and then were
transfected by IKK2EE or MIGRI for 12, 24 and 48 hours. Cells were collected and nuclear proteins were extracted for ELISA-based NF-kB activity assay.
Excess competitor oligonucleotides were coincubated with the nuclear protein of MIGRI-transfected and HSV-2-infected BCBL-1 cells for competition
assays (HSV-2+MIGRI+Comp.). Results presented were the statistic of three independent experiments performed in triplicate. * p,0.05 and ** p,0.01
for Student’s t-test versus Mock+MIGRI group, respectively;
## p,0.01 and
& p,0.01 for Student’s t-test versus HSV-2+MIGRI group, respectively. (B).
Transfection of IKK2EE promoted HSV-2-induced activity of NF-kB in BCBL-1 cells. BCBL-1 cells were infected by HSV-2 or Mock for 1 hour,
and then were co-transfected with the plasmid IKK2EE and an NF-kB-dependent firefly luciferase reporter construct (0.4 mg) together with a Renilla
luciferase construct pRL-TK (0.02 mg) for 12, 24 and 48 hours. Whole-cell extracts were prepared, and the firefly as well as the Renilla luciferase activity
was measured. The experiment was performed three times in parallel, and the mean 6 s.e.m is shown. ** p,0.01 and
## p,0.01 for Student’s t-test
versus Mock+MIGRI and HSV-2+MIGRI groups, respectively. (C). Transfection of IKK2EE inhibited ORF26 mRNA expression in HSV-2-
infected BCBL-1 cells. BCBL-1 cells were infected by HSV-2 or Mock for 1 hour, and then were transfected by IKK2EE or MIGRI for 12, 24 and
48 hours. Cells were collected and ORF26 mRNA expression in BCBL-1 cells was measured by RT-qPCR. Relative quantities of ORF26 expression
represented on the y-axis. Results shown were from three independent experiments performed in triplicate. ** p,0.01 for Student’s t-test versus
Mock+MIGRI group;
# p,0.05 and
## p,0.01 for Student’s t-test versus HSV-2+MIGRI group, respectively. (D). Transfection of IKK2EE inhibited
vIL-6 expression in HSV-2-infected BCBL-1 cells. BCBL-1 cells were infected by HSV-2 or Mock for 1 hour, and then were transfected by IKK2EE
or MIGRI for 12, 24 and 48 hours. Whole cell lysate were subjected to Western blot with the indicated antibody. (E). Real-time DNA-PCR analysis
for the viral copy number of KSHV. BCBL-1 cells were infected by HSV-2 or Mock for 1 hour, and then were transfected by IKK2EE or MIGRI. At 24
and 48 hours postinfection, supernatant virus was collected, concentrated, and used for real-time DNA-PCR analysis. Results shown were from three
independent experiments performed in triplicate. ** p,0.01 and
## p,0.01 for Student’s t-test versus Mock+MIGRI and HSV-2+MIGRI groups,
respectively.
doi:10.1371/journal.pone.0031652.g006
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Cell Culture and Virus Infection
The BCBL-1 and BC-3 cells (EBV-negative and KSHV-positive
PEL cell lines) were obtained through the AIDS Research and
Reference Reagent Program, National Institutes of Health. A
HEK293 cell line that harbors the KSHV genome inserted into a
bacterial artificial chromosome, designated 293/Bac36, was a kind
gift from S-J Gao (University of Southern California, Los Angeles,
CA). B95-8, which were KSHV-negative and EBV-positive
marmoset B-cell lines, HEK293, and Vero (African green monkey
kidney fibroblasts) cells were obtained from American Type
Culture Collection (ATCC, Rockville, MD). Both BCBL-1 and
B95-8 cells were maintained in RPMI-1640 containing 10% heat-
inactivated fetal bovine serum (FBS), 2 mmol/L L-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin. HEK293 and
Vero cells were maintained in DMEM+10% FBS. 293/Bac36 was
grown under the same conditions, except with the addition of
100 mg/mL hygromycin B. HSV-2 (333 strain) propagated in
Vero cells as previously described [11,52]. The supernatants from
normal Vero cells culture were collected and used as a control
(Mock) to treat target cells.
Antibodies and Reagents
Anti-HSV-2 Glycoprotein G-2 (gG-2) mouse monoclonal
antibody (MAb) was purchased from Biodesign International
TM.
Anti-KSHV ORF59 MAb and viral IL-6 (vIL-6) rabbit polyclonal
antibody (PAb) were obtained from Advanced Biotechnologies
Inc. (Columbia, MD). Anti-KSHV Rta (also known as ORF50)
peptide antibodies were generated by immunization of rabbits
with a Rta peptides (aa667–691). The horseradish peroxidase
Figure 7. HIV-1 Tat cooperates with HSV-2 to induce KSHV lytic cycle replication. (A). Effect of Tat on ORF26 mRNA expression in
HSV-2-infected BCBL-1 cells. Real-time quantitative PCR was performed to detect KSHV ORF26 mRNA expression in Mock-treated and pcDNA3.1-
transfected BCBL-1 cells (Mock+pcDNA), Mock-treated and pTat-transfected BCBL-1 cells (Mock+Tat), or HSV-2-infected and pcDNA3.1-transfected
BCBL-1 cells (HSV-2+pcDNA), HSV-2-infected and pTat-transfected BCBL-1 cells (HSV-2+Tat) for 6, 24, 48 and 72 hours. The results shown were
from three independent experiments performed in triplicate. ** p,0.01 for Student’s t-test versus HSV-2+pcDNA group. (B). Effect of Tat on vIL-6
protein expression in HSV-2-infected BCBL-1 cells. Cell lysates were collected from HSV-2-infected and pcDNA3.1-transfected BCBL-1 cells, or
HSV-2-infected and pTat-transfected BCBL-1 cells for 48 and 72 hours. Whole cell lysate were subjected to Western blot with the indicated antibody.
(C). Effect of Tat on Rta promoter activities in HSV-2-infected BCBL-1 cells. BCBL-1, B95-8 and Vero cells were infected with Mock and then
co-transfected with pcDNA3.1, p50-Luc and Renilla vector pRL-TK (Mock+pcDNA3.1), infected with HSV-2 and then co-transfected with pcDNA3.1,
p50-Luc and Renilla vector pRL-TK (HSV-2+pcDNA3.1), or infected with HSV-2 and then co-transfected with pTat, p50-Luc and Renilla vector pRL-TK
(HSV-2+Tat). Luciferase activities were measured, normalized to Rellina inner control, and presented as fold increase (n-fold). All data points were
the averages of three independent experiments performed in triplicate. * p,0.05 and ** p,0.01 for Student’s t-test versus HSV-2+pcDNA3.1 group,
respectively. (D). Effect of Tat on HSV-2 replication in BCBL-1 cells. BCBL-1 cells were infected with Mock and then transfected with pcDNA3.1
(Mock+pcDNA), infected with HSV-2 and then transfected with pcDNA3.1 (HSV-2+pcDNA), or infected with HSV-2 and then transfected with pTat
(HSV-2+pTat) for 24, 48 and 72 hours. Whole cell lysate were subjected to Western blot with the indicated antibody.
doi:10.1371/journal.pone.0031652.g007
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rabbit IgG, and mouse MAb to b-Actin, a-Tubulin and GAPDH
(used to monitor sample loading) were purchased from Santa Cruz
Biotechnologies (Santa Cruz, Calif.). Anti-Flag M2 mouse MAb
were obtained from Cell Signaling Technologies (Beverly, MA,
USA). Bay11-7082 were purchased from Sigma (St. Louis, MO,
USA).
Western Blot Analysis
Western blot was performed as described previously [12].
Proteins were visualized with ECL reagents (Amersham Biosci-
ences, Piscataway, NJ) according to the manufacturer’s instruc-
tions. Western blot experiments were repeated at least three times
to confirm results.
Real-Time Quantitative Reverse Transcription-PCR (RT-
qPCR)
RT-qPCR was performed in the 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA). The sequences of KSHV-
specific primers and probes including Rta and 26 were shown as
previously described [11].
Real-time DNA-PCR Analysis for Viral Copy Number
Real-time DNA-PCR was carried out on viral DNA from
supernatants of BCBL-1 cells essentially as described previously
[53]. Specifically, the primers and probe for the real-time DNA-
PCR were designed to detect ORF26 [12]. Viral DNA was
extracted using the high pure viral nucleic acid kit (Roche,
Germany) as per the manufacturer’s instructions. The KSHV
ORF26 gene cloned in the pcDNA3.1 (Invitrogen, Inc., Carlsbad,
CA) was used to generate the standard curve.
RT-PCR
RT-PCR was performed as previously described [11]. Primers
used for analysis of KSHV genes in this study were also shown as
previously described [11]. Primers used for analysis of HSV-2
genes are listed in Table 1.
Immunofluorescence Assay (IFA)
IFA was performed as described elsewhere. Briefly, after
infection of BCBL-1 cells with HSV-2, cells (10
7/ml) were
washed and smeared on chamber slides. Slides were incubated
with a 1:100 dilution of anti-KSHV ORF59 mouse MAb. Alexa
Fluor 568 (Invitrogen)-conjugated goat anti-mouse antibody
(1:200 dilution) was used as a secondary antibody for detection.
The cells were counterstained with 49,9-diamidino-2-phenylin-
dole. Images were observed and recorded with a Zeiss Axiovert
200 M epifluorescence microscope (Carl Zeiss, Inc.). Photo-
graphs of at least 10 unique fields were taken of every slide, and
the number of positive and negative cells was counted separately
by three individuals, including one who was blinded to the
results to calculate the percentage of positive cells. Immuno-
staining was performed on samples from three separate
experiments.
Plasmid, Transfection and Luciferase Reporter Assay
The pTat plasmid was used as described previously [12]. The
siRNA construct (pRNAT-Rta) that targets KSHV Rta was
utilized as previously described [11]. NF-kB reporter plasmid
containing three tandem repeats of consensus NF-kB binding sites
was obtained from Huaguo Xu (Department of Clinical
Laboratory, Nanjing Medical University, Nanjing, China).
IKK2EE capable of phosphorylating IkBa and control vector
MIGRI were kindly provided by Zan Huang (Wuhan University
School of Life Science, Wuhan, China). The KSHV Rta luciferase
reporter construct (p50-Luc) was generated as described previously
[12]. Before transfection, cells were adsorbed with HSV-2 for
1 hour. After 48-hour transfection, cells were harvested for
luciferase assay. Renilla vector pRL-TK (Promega) was used as
an internal control and relative luciferase activity was assayed
using the Promega dual-luciferase reporter assay system. BCBL-1,
BC-3 and B95-8 cells were electroporated at 250 V and 960
microfarads using a Gene Pulser (Bio-Rad Laboratories, Hercules,
CA) as described previously [43]. Both 293/Bac36 and Vero cells
were transfected with Lipofectamine 2000 (Invitrogen) following
the manufacturer’s instructions.
ELISA-based Transcription Factor Activity Assay
The activation of the transcription factor NF-kB was assayed by
using TransFactor NF-kB p65 Colorimetric Kit from Clontech
Laboratories, Inc (California, USA) under conditions recom-
mended by the manufacturer and as described elsewhere [54].
Nuclear protein of BCBL-1 cells was extracted using the Nuclear
Extract Kit (Active Motif, CA, USA) and ELISA-based transcrip-
tion factor activity assay was performed following the manufac-
turer’s protocol. For competition assays, competitor oligonucleo-
tides were added to coincubate with nuclear protein. Samples were
run in triplicates, and all experiments were performed on three
occasions.
Table 1. Sets of primers of HSV-2 used for RT-PCR.
mRNA Oligonucleotides Accession no.
Expected
size (bp)
Annealing
temp (6C) Cycles
UL48 F:59-GAG CAG GCC CTC GAT TGT C-39
R:59-CCA GTT GGC GTG TCT GTT TCA-39
NC-001798.1 352 58 29
UL5 F:59-GTG ATG CGA CTG GCG TTG G-39
R:59-CAG TTT GTG GAC CGC TTT GT-39
NC-001798.1 278 58 30
US6 F:59-GCG TGT TTA CCA CAT TCA GCC-39
R:59-TCC GTC CAG TCG TTT ATC TTC A-39
NC-001798.1 420 58 29
b-Actin F:59-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-39
R:59-CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG-39
BC016045 661 56 24
The oligonucleotides were selected from the sequences with the indicated accession number. The size of each amplified product, its annealing temperature, and
numbers of PCR cycles are indicated. F, forward; R, reverse.
doi:10.1371/journal.pone.0031652.t001
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